GI Symposium Colorectal Cancer Spotlight | Conferences

January 28, 2021

Zev A. Wainberg, MD, discusses the impact of the COVID-19 on the colorectal cancer field specifically in terms of clinical trial research.

January 28, 2021

John L. Marshall, MD, discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology.

January 27, 2021

Tanios S. Bekaii-Saab, MD, discusses genetic testing and emerging precision medicine strategies in the field of colorectal cancer.

January 27, 2021

The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity among patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild-type, according to findings from a phase 2 LCCC1632 study.

January 20, 2021

John H. Strickler, MD, discusses dosing of regorafenib in patients with colorectal cancer.

January 19, 2021

Kanwal Raghav, MBBS, MD, discusses factors that should be considered when deciding on treatment for a patient with metastatic colorectal cancer.

January 18, 2021

Zev A. Wainberg, MD, explains the importance of having a chemotherapy-free option available for patients with colorectal cancer.

January 18, 2021

The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.

January 17, 2021

The frontline combination of trifluridine/tipiracil in combination with bevacizumab demonstrated an overall survival benefit compared with capecitabine and bevacizumab as treatment of patients with unresectable metastatic colorectal cancer who are not eligible for a standard chemotherapy regimen, resulting in a difference of almost 5 months, according to the final analysis of the phase 2 TASCO1 trial.

January 16, 2021

The use of pembrolizumab monotherapy upfront significantly improved progression-free survival while demonstrating superior safety, compared with chemotherapy, in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.